Brief: Gensight Biologics Receives FDA Fast Track Designation For GS030 Treatment

Gensight Biologics SA

12/10/2021 06:40

Oct 12 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES FDA GRANT OF FAST TRACK
DESIGNATION
FOR OPTOGENETIC THERAPY GS030 AS TREATMENT FOR RETINITIS
PIGMENTOSA
    * GFOOD & DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK
DESIGNATION TO GS030, WHICH COMBINES AAV2-BASED GENE THERAPY
WITH OPTOGENETICS TO TREAT RETINITIS PIGMENTOSA (RP)
    * WE ARE IN A GREAT POSITION IN OUR QUEST TO PROVIDE A
CUTTING-EDGE TREATMENT FOR RETINITIS PIGMENTOSA PATIENTS - CEO
    * FAST TRACK IS PROCESS TO FACILITATE DEVELOPMENT AND
EXPEDITE
REVIEW OF DRUGS FOR TREATMENT OF SERIOUS CONDITIONS WHERE THERE
IS UNMET MEDICAL NEED

Source text for Eikon:  ID:nBw3x88hra 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))